NICE recommends garadacimab for prevention of HAE attacks
The UK National Institute for Health and Care Excellence (NICE) has recommended Andembry (garadacimab) for the prevention of hereditary angioedema (HAE) attacks, biopharmaceutical company CSL Behring has announced.
The recommendation follows results from the Phase III VANGUARD trial, which found garadacimab significantly reduced the mean number of monthly HAE attacks compared to placebo by 87%, with 62% of patients consistently attack free over six months. Garadacimab has subsequently been recommended for the prevention of HAE in people 12 years and older.
HAE is a rare, chronic, debilitating and potentially life-threatening genetic condition characterised by recurrent and unpredictable attacks of angioedema, which result in painful swelling in different areas of the body, particularly the abdomen, larynx, face and extremities (hands and feet). The condition affects approximately one in 50,000 people in the UK and can have a profound impact on quality of life, with many patients living in constant fear of the next attack.
“HAE UK welcome NICE’s recommendation, which represents a step forward in reducing the burden of this condition,” said Angela Metcalfe, Chief Executive Officer of patient support group HAE UK. “Improving patient choice by enabling access to new treatments in HAE is vital due to the highly individual nature of this condition, which can impact almost every aspect of a patient’s life.”
Garadacimab offers ‘meaningful reduction’ of HAE attacks
Despite the availability of effective therapies, patients with HAE may still experience breakthrough attacks, often requiring frequent on-demand treatment. Patients with HAE report a high frequency of anxiety and depression associated with the fear of attacks, that worsen with attack frequency. HAE also affects daily function, impacting work productivity, career advancement and educational choices.
It is hoped garadacimab, which is delivered via a pre-filled pen, will offer effective prevention of HAE attacks. It inhibits the plasma protein factor XIIa which, when activated, initiates the cascade of events leading to oedema at various sites of the body. By preventing attacks before they occur, garadacimab has shown to offer greater attack freedom versus placebo, and provides an additional treatment option for managing the condition proactively.
Results from the VANGUARD Phase III trial, first published in The Lancet in April 2023, evaluated the efficacy and safety of garadacimab. During the six-month treatment period, garadacimab significantly reduced the frequency and severity of HAE attacks compared to placebo. There were adverse events recorded in the garadacimab group of the trial, including upper-respiratory tract infections (10%, n=4), nasopharyngitis (8%, n=3), and headaches (8%, n=3), but overall results proved the efficacy and safety of the drug.
Dr Anthony Dorr, a Consultant Clinical Immunologist who works with HAE patients in London, said: “The clinical data highlights that garadacimab offers a meaningful reduction in hereditary angioedema attack frequency and severity, with a novel mechanism of action and monthly dosing.”
Bruno Quinney, Content Team, DDW
